---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108846"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:09:04.796352+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Clearside receives Nasdaq delisting notice; Chairperson Gibney resigns, Thorp succeeds

## Summary
- Nasdaq notified Clearside on Aug 11, 2025 that its common stock is subject to delisting due to bid price below $1.00 for 30 consecutive business days.
- Clearside intends to request a hearing before Nasdaq Panel to stay delisting; stock will continue trading pending hearing process.
- Company is seeking stockholder approval for a reverse stock split at ratio 1-for-5 to 1-for-15 to regain minimum bid price compliance.
- Anthony Gibney resigned as Chairperson and board member effective Aug 11, 2025; appointed CFO of Aura Biosciences; no dispute.
- Board appointed existing member Clay B. Thorp as new Chairperson effective Aug 13, 2025.

## SEC filing metadata
- accession: 0000950170-25-108846
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017025108846/0000950170-25-108846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017025108846/clsd-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108846
- JSON: https://secwatch.observer/filing/0000950170-25-108846.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108846.txt

## Key facts
- Listing & Compliance Notices
  Clearside Biomedical, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)
  source text: previously disclosed, on February 7, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days (the “ Minimum Bid Price Requirement ”). As the Company did not regain compliance with the Minimum Bid Pric
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017025108846/0000950170-25-108846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.